Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Abbott: Brave or Stupid?

On Thursday, Abbott Labs (NYSE: ABT  ) announced the acquisition of PanGenetics' pain drug PG110. Now I'm wondering how much this acquisition will hurt the company's ego.

Compare the structure of this deal with other recent deals:



Up Front




$170 million

$20 million

Bristol-Myers Squibb (NYSE: BMY  )

Alder Biopharmaceuticals

$85 million

May exceed $964 million*

AstraZeneca (NYSE: AZN  )

Nektar Therapeutics (Nasdaq: NKTR  )

$125 million

$610 million*

GlaxoSmithKline (NYSE: GSK  )

Idenix Pharmaceuticals

$34 million**

$416 million*

Biogen Idec (Nasdaq: BIIB  )

Acorda Therapeutics (Nasdaq: ACOR  )

$110 million

$400 million*

Source: Company press releases.*Out-licenser is also due royalties.** Includes equity investment.

You can ignore the absolute values; the drugs are at different stages of development, and some deals include more than one drug. The important thing to notice is that Abbott is taking on most of the risk with the relatively larger up-front payment, and it'll only be on the hook for an additional $20 million if PG110 works. In all the other cases, the buyers have assumed less risk by tying the majority of payments to getting the drugs through the clinical trial process, getting them past the regulatory agencies, and then getting them to sell well.

Of course, the lower risk comes at a price. Abbott's only on the hook for $190 million total, and it doesn't appear to owe PanGenetics any royalties if the drug makes it to market. That'll make the drug look like a steal if PG110 succeeds.

Unfortunately, PG110 is only in phase 1 trials, so it'll be a few years before investors find out whether Abbott's gamble paid off.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 13, 2009, at 11:45 PM, wolfhounds wrote:

    That's it? A drug company decides to take a risk and you state the obvious?

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1043007, ~/Articles/ArticleHandler.aspx, 10/21/2016 7:32:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:01 PM
ABT $40.74 Up +0.73 +1.82%
Abbott Laboratorie… CAPS Rating: *****
ACOR $20.20 Up +0.15 +0.75%
Acorda Therapeutic… CAPS Rating: ****
AZN $31.00 Up +0.22 +0.71%
AstraZeneca CAPS Rating: ****
BIIB $299.66 Up +4.52 +1.53%
Biogen CAPS Rating: *****
BMY $50.36 Up +0.49 +0.98%
Bristol-Myers Squi… CAPS Rating: ****
GSK $41.43 Down -0.06 -0.14%
GlaxoSmithKline CAPS Rating: ***
NKTR $13.75 Up +0.40 +3.00%
Nektar Therapeutic… CAPS Rating: ***